Testing QL2401 for Fatty Liver Disease with Scarring
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug called QL2401 to see if it can improve fatty liver disease (MASH) in people who also have diabetes, obesity, or related conditions. The drug is designed to reduce liver fat and slow scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Type 2 diabetes OR at least one of: obesity, high cholesterol, high blood pressure, or high fasting blood sugar
- Moderate liver scarring (fibrosis stage 2–3), confirmed by biopsy or liver stiffness measurement
- More than 10% fat in your liver, measured by a special MRI scan
- If taking weight-loss, blood-sugar, or cholesterol medications, you must have been on a stable dose for 3+ months
- Stable body weight (within 5% change) for the 2 months before screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called QL2401 in healthy adults to see if it is safe and how the body processes it. If you are a generally healthy Chinese adult aged 18 to 45, you may be able to help researchers understand this drug's effects.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
This study tests a new drug called ALN-CIDEB for adults with MASH (a type of liver disease linked to metabolic health issues like obesity and diabetes). The drug aims to slow or reverse liver scarring (fibrosis) in people with moderate damage.
Hear when a new Metabolic Dysfunction-associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.